# EDGAR Filing Document

**Accession Number:** 0001473930
**File Stem:** 0001473930-26-000004
**Filing Date:** 2026-1
**Character Count:** 6441
**Document Hash:** 0b03e73dff7c37f913a6637c64479ea0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001473930-26-000004.hdr.sgml**: 20260108

**ACCESSION NUMBER**: 0001473930-26-000004

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260108

**FILED AS OF DATE**: 20260108

**DATE AS OF CHANGE**: 20260108

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foley Todd
- **CENTRAL INDEX KEY:** 0001473930

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43047
- **FILM NUMBER:** 26521176

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET
- **STREET 2:** SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aktis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0002035832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852584233
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 978-237-4380

**MAIL ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foley Todd<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Aktis Oncology, Inc. [ AKTS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-01-08 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series Seed Redeemable Convertible Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 597391 | 0<sup>(1)</sup> | I | See Footnote<sup>(2)(3)</sup> |
| Series A Redeemable Convertible Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 2688270 | 0<sup>(1)</sup> | I | See Footnote<sup>(2)(4)</sup> |
| Series B Redeemable Convertible Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 716872 | 0<sup>(1)</sup> | I | See Footnote<sup>(2)(5)</sup> |
| Stock Option (Right to Buy) | <sup>(6)</sup> | 2036-01-07 | Common Stock | 37866 | $18 | D |  |

---

### Footnotes:

(1) Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis.  Upon the closing of the Issuer's initial public offering, all shares of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock will convert into shares of Common Stock of the Issuer.  The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock have no expiration date.

(2) The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

(3) The shares are held as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"),
29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.

(4) The shares are held as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.

(5) The shares are held as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.

(6) 1/36th of the original number of shares subject to the  option shall vest in monthly installments from January 8, 2026, subject to the Reporting Person's continuous service through each vesting date, inclusive.

**Signature:** /s/ Todd Foley  
**Date:** 2026-01-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**